There remain considerable prospects and challenges for the use of NLRP3 blockade to treat NAFLD/NASH, and optimization of the therapeutic strategy for NAFLD remains a major challenge. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.